Migalastat is covered for the 35-50% of GCC Fabry patients with an amenable mutation, but fewer than 15% have been tested — the HEK293 assay runs at just one lab across six countries.
Classic Fabry disease prevalence in GCC is estimated at 1:20,000-30,000 males, elevated above the global 1:40,000 rate by founder mutations concentrated in consanguineous families. The KFSH&RC Fabry registry has documented more than 15 unique GCC family clusters sharing GLA mutations, and family-based cascade screening at index-case diagnosis yields an estimated 3-5 additional affected members per family — nearly triple the 1.8 seen in global series. Agalsidase beta (Fabrazyme), SFDA-registered since 2003 and covered by NPHC for confirmed Fabry disease with documented GLA enzyme deficiency, is the dominant enzyme replacement therapy, administered at KAMC, KFSH&RC, AUH, and Hamad Medical Corporation through an established infusion-centre network.
GCC is structurally a two-ERT market in a way the US is not: agalsidase alfa (Replagal), EMA-approved in 2001 but never FDA-approved, reaches GCC patients via SFDA's EMA-pathway registration and Takeda's regional distribution. Some NPHC-approved patients are maintained on agalsidase alfa specifically during Fabrazyme global supply constraints, as occurred in 2010 and 2022. Migalastat (Galafold), the oral chaperone SFDA-registered in 2020 and MOH UAE-registered in 2021, is covered for the estimated 35-50% of GCC Fabry patients carrying an amenable GLA mutation — but eligibility requires an HEK293 cell-based assay available at only one laboratory in the entire region, KFSH&RC, with a 6-8 week turnaround for samples sent from elsewhere in the Gulf. Fewer than 15% of amenable-mutation candidates have been formally tested, making mutation-testing access, not clinical evidence, the binding constraint on oral-therapy uptake.
Approved Fabry disease agents — GCC, 2024
| Drug (Brand / INN) | Mechanism | Company | GCC Registration | Key Trial Result | GCC Access Status |
|---|---|---|---|---|---|
| Fabrazyme (agalsidase beta) | ERT IV | Sanofi Genzyme | SFDA registered 2003; NPHC covered | GL-3 clearance — Phase 3 RCT evidence base | Dominant; NPHC-listed; administered at KAMC/KFSH&RC/AUH/HMC infusion network |
| Replagal (agalsidase alfa) | ERT IV — EMA-approved, not FDA-approved | Takeda / Shire | SFDA registered via EMA pathway | Equivalent to agalsidase beta (TKT Phase 2/3) | Available via import; some NPHC-approved patients maintained during Fabrazyme supply constraints |
| Galafold (migalastat) | Oral chaperone — mutation-gated | Amicus Therapeutics | SFDA 2020; MOH UAE 2021 | Non-inferior to ERT in amenable mutations (ATTRACT/FACETS) | Covered for amenable mutations; HEK293 assay available only at KFSH&RC |
Sources: SFDA registration records; NPHC Fabry disease programme 2023; ATTRACT and FACETS trials (migalastat); TKT Phase 2/3 (agalsidase alfa); Al-Hassnan ZN et al. Saudi Med J 2010; KFSH&RC Fabry disease registry; Takeda GCC distribution data; KFSH&RC genetics laboratory capacity report 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- SFDA EMA-pathway registration mechanics for agalsidase alfa
- NPHC switch/supply-continuity practice during Fabrazyme constraints
- Takeda vs Sanofi Genzyme distribution footprint
Delivers
- Current testing-capacity bottleneck and 6-8 week turnaround
- send-out/partnership models under discussion
- the amenable-mutation share (35-50%) as a commercial ceiling estimate
Delivers
- KFSH&RC Fabry registry cascade-screening yield (3-5 additional members per index case)
- centre network (KAMC, KFSH&RC, AUH, HMC)
- demand-forecasting implications
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- How the KFSH&RC Fabry registry has documented more than 15 unique GCC family clusters sharing GLA mutations, tied to founder-mutation concentration in consanguineous families.
- Why family-based cascade screening at index-case diagnosis yields an estimated 3 to 5 additional affected members per family, nearly triple the 1.8 seen in global series.
- Fabrazyme (agalsidase beta), SFDA-registered since 2003 and NPHC-covered, remains the dominant ERT, administered at KAMC, KFSH&RC, AUH, and Hamad Medical Corporation.
- Galafold (migalastat), SFDA-registered in 2020 and MOH UAE-registered in 2021, is covered for the estimated 35 to 50% of patients carrying an amenable GLA mutation.
- Why Replagal (agalsidase alfa), EMA-approved in 2001 but never FDA-approved, reaches GCC patients only through SFDA's EMA-pathway registration and Takeda's regional distribution.
- How some NPHC-approved patients are maintained on agalsidase alfa specifically during Fabrazyme global supply constraints, as occurred in 2010 and 2022.
- Why migalastat eligibility requires an HEK293 cell-based assay available at only one laboratory in the entire region, KFSH&RC, with a 6 to 8 week turnaround for samples sent from elsewhere in the Gulf.
- How fewer than 15% of amenable-mutation candidates have been formally tested, making mutation-testing access, not clinical evidence, the binding constraint on oral-therapy uptake.
- How Fabrazyme's SFDA registration since 2003 and NPHC coverage require documented GLA enzyme deficiency for confirmed Fabry disease.
- Why migalastat's SFDA registration in 2020 and MOH UAE registration in 2021 came years before broad mutation-testing capacity existed to support it.
- Which four centres, KAMC, KFSH&RC, AUH, and Hamad Medical Corporation, form the established ERT infusion-centre network across the GCC.
- Why KFSH&RC's dual role, the region's only HEK293 assay site and a core ERT infusion centre, makes it the central node in GCC Fabry disease management.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, SFDA, MOH, ClinicalTrials.gov), peer-reviewed literature, and live payer/formulary policy documentation — not secondary summaries. Findings are independently verified before inclusion.
Fabry Disease GCC CI sources: SFDA registration records, NPHC Fabry disease programme 2023, ATTRACT and FACETS trials (migalastat), TKT Phase 2/3 (agalsidase alfa), Al-Hassnan ZN et al. Saudi Med J 2010, KFSH&RC Fabry disease registry, Takeda GCC distribution data, and KFSH&RC genetics laboratory capacity report 2023.
- Drug registration status verified against SFDA and MOH UAE formulary documentation
- Clinical trial results verified against published primary sources (ATTRACT, FACETS, TKT Phase 2/3)
- GCC prevalence and family-cluster figures verified against KFSH&RC Fabry disease registry and published epidemiology (Al-Hassnan ZN et al.)
- Mutation-testing capacity verified against KFSH&RC genetics laboratory capacity reporting and NPHC Fabry programme notes
Frequently asked questions
Commission this brief
AXLRx delivers Fabry Disease competitive intelligence for the GCC market, built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.